RCMI Coordinating Center (RCMI CC) Header Logo

Connection

Narendiran Rajasekaran to Esophageal Neoplasms

Back to Details
This is a "connection" page, showing publications Narendiran Rajasekaran has written about Esophageal Neoplasms.
Narendiran Rajasekaran
Connection Strength
0.847
Esophageal Neoplasms
  1. Rajasekaran N, Wang X, Ravindranathan S, Chin DJ, Tseng SY, Klakamp SL, Widmann K, Kapoor VN, Vexler V, Keegan P, Yao S, LaVallee T, Khare SD. Toripalimab, a therapeutic monoclonal anti-PD-1 antibody with high binding affinity to PD-1 and enhanced potency to activate human T cells. Cancer Immunol Immunother. 2024 Feb 24; 73(3):60.
    View in: PubMed
    Score: 0.847
Connection Strength

The connection strength for concepts is the sum of the scores for each matching publication.

Publication scores are based on many factors, including how long ago they were written and whether the person is a first or senior author.
RCMI CC is supported by the National Institute on Minority Health and Health Disparities, National Institutes of Health (NIH), through Grant Number U24MD015970. The contents of this site are solely the responsibility of the authors and do not necessarily represent the official views of the NIH

For technical support please contact support